Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go:
TBC
investment:
Withheld
Supper aims to be a unique delivery service focusing on quality and service for high-end restaurants. It argues that its commercial metrics and lack of reliance on 'Gig-Economy' workers sets it apart from competitors. The company intends to become a contender in the food delivery market that grew by 35% in 2020 and by almost 150% over the last 5 years. It has partnered with 130 notable establishments such as Zuma, Park Chinois, Milos, and Cova, to name a few. Supper has 61,000 customers on its portal that is further growing by 1,500 new customers every month. The company delivers 1,000 orders each week and has fulfilled 100,000 orders to date with the average order costing £100. It delivers orders via its purpose-built, gyroscopically-stable, and temperature-controlled vehicles. Supper will use the investment to focus on its growth in London and expand globally.
days to go:
Expired
investment:
Withheld
Elfin Market aims to revolutionize the credit card industry by making credit cards more affordable, fair, and straightforward. They launched the Elfin Card, offering flexible credit that is 50% cheaper than the average credit card, featuring transparent pricing and state-of-the-art iOS and Android apps for real-time account management. The company operates on a flat servicing fee of 2.5% before transferring interest from borrowers to lenders, providing a simpler and more cost-effective credit solution.
days to go:
Expired
investment:
£1,390,059
HaMuch is an online platform that lets homeowners compare hourly rates of local tradespeople and check their availability. The company has provided digital marketing services to businesses such as Travis Perkins, HomeServe, and Rated People. About 200,000 tradespeople have uploaded their profiles on the platform with 12,000+ having uploaded their respective prices. The company has been featured in The Sunday Telegraph, Express, Sun, and Microsoft News.
days to go:
Expired
investment:
£132,850
Creating Scottish cocktails that are high quality and ready-to-drink. The Venom Project's drinks consist of 5 flavours available in cans that contain 8% alcohol and are currently sold in off-licenses in Scotland, as well as over 300 retailers. In the first 7 months of trading, the company has been listed by over 250 stockists and sold more than 150k units. This has resulted in sales of £500k with the team growing from 3 to 10 members to handle demand.
More than 250 stores have requested re-orders on a monthly basis and The Venom Project has predicted that 250k units per month will be reached in the near future. Funds will allow the company to escalate their manufacturing process to meet consumer demand, as well as acquire more stockists to attract new customers to the brand. A new manufacturing process will also allow the business to print their cans, which will aid in reducing production costs.
days to go:
Expired
investment:
£62,170
Morso London is a modern community-centred restaurant that serves hand-crafted freshly made pasta and Italian bites with grappa-based cocktails. Launched in June 2018, the restaurant is created by a team of industry veterans. Paolo Vernetti is the Co-founder, head chef and CEO of Morso. Since Dec 2018, Morso has been TripAdvisor's Top 50 restaurant. The restaurant has received more than 100 5 star reviews. Morso was covered by Fay Maschler’s “Week in Food”, The Upcoming, The Infatuation and many other important food/media publications. Morso has achieved a 3x weekly sales growth from June 2018 to Jan 2019. It is achieving a positive site EBITDA on the 6th month of trading. Morso is planning to grow by opening two more sites in 2019.
days to go:
Expired
investment:
£99,950
